About this item:

253 Views | 221 Downloads

Author Notes:

Corresponding author: Alessandra C. Schmitt, MD, Emory University Hospital Midtown, Department of Pathology, 550 Peachtree Street NE, Davis Fisher Building Suite 1314-A, Atlanta, GA, 30308, Tel: 404.686.3733, Fax: 404.686.4978, alessandra.schmitt@emory.edu

The authors have no conflicts of interest.


Research Funding:

Supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR000454.


  • Science & Technology
  • Life Sciences & Biomedicine
  • Medical Laboratory Technology
  • Pathology
  • aspiration cytology
  • basaloid neoplasms
  • immunohistochemistry
  • LEF-1
  • salivary gland neoplasms
  • HAIR

LEF-1: Diagnostic utility in distinguishing basaloid neoplasms of the salivary gland


Journal Title:

Diagnostic Cytopathology


Volume 45, Number 12


, Pages 1078-1083

Type of Work:

Article | Post-print: After Peer Review


Background: Lymphoid enhancer binding factor 1 (LEF-1) has recently been reported as a potential immunohistochemical (IHC) marker for basal cell adenoma (BCA) and other salivary gland tumors, which may contribute to an increased accuracy in differentiating basaloid salivary gland neoplasms. We evaluated the utility of LEF-1 in fine needle aspiration (FNA) and resection specimens to distinguish pleomorphic adenoma (PA), BCA, basal cell adenocarcinoma (BCAC), and adenoid cystic carcinoma (ACC) as well as in non-neoplastic salivary gland (NNSG). Methods: Cases including 66 PA (35 FNA, 31 resections), 12 BCA (5 FNA, 7 resections), 42 ACC (11 FNA, 31 resections), 1 BCAC FNA, and 10 NNSG (5 FNA, 5 resections) were obtained and stained for LEF-1. Results: On cell block (CB), 51% of PA and 60% of BCA were LEF-1 positive while 91% of ACC were LEF-1 negative. Among resections, there was a higher percentage of LEF-1 positive PA (84%) and BCA (86%), and a higher percentage of LEF-1 negative ACC (97%). LEF-1 staining had a low to moderate sensitivity for detecting benign basaloid neoplasms on FNA CB and resection specimens (52.5% and 84%, respectively), but a higher specificity (92% and 97% respectively), and positive predictive value (95% and 97% respectively). Conclusion: When comparing benign (PA and BCA) and the most common malignant basaloid salivary gland tumor (ACC), positive LEF-1 favors a benign neoplasm. Additional studies with LEF-1, specifically including other rare basaloid salivary gland neoplasms are needed to further clarify the role of LEF-1 in diagnosing these lesions on FNA.

Copyright information:

© 2017 Wiley Periodicals, Inc.

Export to EndNote